Simplex LAB Spółka z Ograniczoną Odpowiedzialnością (KRS 0001078559, NIP 5242994455) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. Simplex LAB operates in: Manufacture of medical and dental instruments and supplies (PKD 32.50.Z). Industry: Other manufacturing. The company has been listed in the National Court Register since January 4, 2024. Simplex LAB's most recently reported net revenue was 164.1 K PLN for 2024.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Simplex LAB
Identity
- Name
- Simplex LAB Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- January 4, 2024
- Registry status as of
- July 16, 2026
- Latest entry
- July 16, 2026
- Founding act
- 28.12.2023
Articles of association history (2)
- December 28, 2023: 28.12.2023
- January 5, 2024: 05.01.2024 R. - ZMIANA § 2
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. WOLIŃSKA, 4, 03-699, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - Simplex LAB
Credibility rating
60 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
2
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany nazwy spółki. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
0
0/3 yrs
Board changes
0
0/3 yrs
PKD changes
0
0/3 yrs
Name changes
1
1/3 yrs
Data from 3 years of registry activity.
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Simplex LAB
Founded
January 4, 2024
2 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
32.50.Z
Manufacture of medical and dental instruments and supplies
Share capital
5.0 K PLN
50 shares total
Shareholders
2
shareholders
Board
2 people
Filed years
1 year
2024
Registry entries
10
latest: July 16, 2026
Revenue
164.1 K PLN
2024
Net profit
11.4 K PLN
2024
Assets
36.2 K PLN
2024
Equity
16.4 K PLN
2024
Valuation
72.3 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Simplex LAB.
No ratings
Related articles
News
Mennica Polska 2026: Q1 revenue up 80% YoY (PLN 726.7m), 838 kg of investment gold, Bulwary Praskie 95% sold, PLN 1.50 dividend
Warsaw-based Mennica Polska S.A. (KRS 0000019196), the only Polish producer of investment-gold bars, with three independent business legs (minting, the City Card transit-ticketing business, and the Bulwary Praskie development), posted Q1 2026 revenue of PLN 726.7m (+80% YoY versus PLN 402.9m) and EBITDA of PLN 56.4m (+28%). Investment-gold sales: 838 kg (+38% by weight YoY). 2025 closed with revenue of around PLN 1.83bn (+31%), EBITDA of around PLN 160m (+29%), and net profit of around PLN 500m (a significant part from the development segment). Bulwary Praskie: 747 apartments with occupancy permits, 95% sold or reserved. Recommended dividend: PLN 1.50 per share (PLN 76.5m).
Explainer
Mercator Medical in 2026: a Kraków-based medical-glove producer with plants in Thailand, an mWIG40 issuer after the COVID meme-stock cycle
Mercator Medical S.A. (KRS 0000036244), headquartered at ul. Modrzejewskiej 30 in Kraków, is a Polish producer and distributor of single-use medical gloves (nitrile and latex) and other disposables. The company controls the full value chain: plants in Thailand (Mercator Medical Thailand) plus Polish and international distribution. In 2020 the share price exploded on pandemic demand (from PLN 10 to over PLN 800), followed by a gradual normalisation. Listed on the WSE since 2013, with a three-member management board and a five-member supervisory board.
